Loading patent…
AssigneeIntercell AG
InventorsSharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander von Gabain
Estimating the term…
The present invention relates to isolated nucleic acid molecules which encode an antigen, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Klebsiella species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. Moreover, the present invention provides antibodies binding to such antigen, a hybridoma cell producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of reducing or inhibiting the interaction activity of such antigen, methods for diagnosing an infection and methods for the treatment or prevention of an infection. More specifically such antigens are produced by or associated with bacterial pathogens causing nosocomial infections or bacterial infections caused by Klebsiella pneumoniae.
An isolated nucleic acid molecule encoding an antigen or a fragment thereof, comprising a nucleic acid sequence, which is selected from the group consisting of:
(canceled)
(canceled)
An antigen that is immunologically reactive with sera from a human having a Klebsiella infection, or from an uninfected healthy human who was previously infected with Klebsiella.
An antigen comprising or consisting of an isolated polypeptide selected from the group consisting of Seq ID Nos:
21-22. (canceled)
(canceled)
An antigen comprising at least one core amino acid sequence as indicated in column “Predicted immunogenic aa” or “Location of identified immunogenic region” of Table 1, or as defined by columns “From aa” and “To aa” of Table 4, or as indicated in column “Location in protein (aa)” of Table 5, whereby more preferably the core amino acid sequence is selected from the group consisting of:
(canceled)
29-38. (canceled)
40-59. (canceled)
62-63. (canceled)
Dependencies are inferred from the claim text.